loading
Schlusskurs vom Vortag:
$0.7217
Offen:
$0.7275
24-Stunden-Volumen:
584.29K
Relative Volume:
0.35
Marktkapitalisierung:
$24.89M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-98.79M
KGV:
-0.2294
EPS:
-3.27
Netto-Cashflow:
$-51.66M
1W Leistung:
+17.30%
1M Leistung:
+163.99%
6M Leistung:
-75.17%
1J Leistung:
-75.33%
1-Tages-Spanne:
Value
$0.692
$0.7689
1-Wochen-Bereich:
Value
$0.6204
$0.7689
52-Wochen-Spanne:
Value
$0.2404
$4.47

Relmada Therapeutics Inc Stock (RLMD) Company Profile

Name
Firmenname
Relmada Therapeutics Inc
Name
Telefon
646 876 3459
Name
Adresse
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
Name
Mitarbeiter
17
Name
Twitter
@relmada
Name
Nächster Verdiensttermin
2025-03-25
Name
Neueste SEC-Einreichungen
Name
RLMD's Discussions on Twitter

Vergleichen Sie RLMD mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
3.03 0 0 0 0 0.00
 icon
GOODO
Gladstone Commercial Corporation
20.43 372.90M 0 0 0 0.00
 icon
JUNE
Dhandho Junoon Etf
11.50 190.93M 0 0 0 0.00
 icon
SHMD
Schmid Group N V
2.76 131.34M 0 0 0 0.00
 icon
PSNYW
Polestar Automotive Holding Uk
0.1601 350.74M 2.07B -1.42B -1.37B -0.6765
 icon
MOBBW
Mobilicom Limited Warrants
0.4197 636.80M 0 0 0 0.00

Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-05 Herabstufung Mizuho Outperform → Neutral
2024-09-17 Hochstufung Jefferies Hold → Buy
2024-06-05 Herabstufung Goldman Neutral → Sell
2022-10-14 Herabstufung Goldman Buy → Neutral
2022-10-14 Herabstufung Guggenheim Buy → Neutral
2022-10-14 Herabstufung Truist Buy → Hold
2022-10-13 Herabstufung Oppenheimer Outperform → Perform
2021-11-18 Eingeleitet Mizuho Buy
2021-05-20 Fortgesetzt Goldman Buy
2020-10-28 Herabstufung Goldman Buy → Neutral
2020-07-14 Eingeleitet Oppenheimer Outperform
2020-05-04 Eingeleitet SunTrust Buy
2020-04-21 Eingeleitet Goldman Buy
2020-01-27 Eingeleitet Jefferies Buy
2020-01-10 Eingeleitet SVB Leerink Outperform
2019-12-16 Eingeleitet Guggenheim Buy
Alle ansehen

Relmada Therapeutics Inc Aktie (RLMD) Neueste Nachrichten

pulisher
May 27, 2025

Relmada Therapeutics Holds Annual Stockholders Meeting - TipRanks

May 27, 2025
pulisher
May 24, 2025

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Receives Consensus Rating of “Hold” from Brokerages - Defense World

May 24, 2025
pulisher
May 24, 2025

Relmada Therapeutics (NASDAQ:RLMD) Lowered to Strong Sell Rating by Wall Street Zen - Defense World

May 24, 2025
pulisher
May 20, 2025

RELMADA THERAPEUTICS Executives Make Significant Stock Purchases in May 2025 - TradingView

May 20, 2025
pulisher
May 20, 2025

Relmada Therapeutics Executives Make Bold Stock Purchases! - TipRanks

May 20, 2025
pulisher
May 16, 2025

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Relmada Therapeutics (RLMD) and Roivant Sciences (ROIV) - The Globe and Mail

May 16, 2025
pulisher
May 15, 2025

Relmada Therapeutics’ Earnings Call: Promising Data Amid Financial Concerns - TipRanks

May 15, 2025
pulisher
May 13, 2025

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2025 Earnings Call Transcript - Insider Monkey

May 13, 2025
pulisher
May 13, 2025

Earnings call transcript: Relmada Therapeutics’ Q1 2025 results miss EPS expectations - Investing.com

May 13, 2025
pulisher
May 13, 2025

Relmada Therapeutics Inc (RLMD) Q1 2025 Earnings Call Highlights: Promising Pipeline ... - Yahoo Finance

May 13, 2025
pulisher
May 13, 2025

Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times

May 13, 2025
pulisher
May 13, 2025

Relmada Therapeutics Inc (RLMD) Q1 2025 Earnings Call Highlights - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Relmada Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 13, 2025
pulisher
May 10, 2025

Relmada Therapeutics to Report First Quarter 2025 Financial Resu - GuruFocus

May 10, 2025
pulisher
May 10, 2025

Relmada Therapeutics (RLMD) Expected to Announce Earnings on Monday - Defense World

May 10, 2025
pulisher
May 08, 2025

Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 - The Manila Times

May 08, 2025
pulisher
May 08, 2025

Relmada Therapeutics, Inc. Announces Conference Call to Discuss Q1 2025 Financial Results and Business Progress - Nasdaq

May 08, 2025
pulisher
May 08, 2025

Renaissance Technologies LLC Buys 138,625 Shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD) - Defense World

May 08, 2025
pulisher
May 02, 2025

Relmada Therapeutics Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView

May 02, 2025
pulisher
May 01, 2025

Chief Executive Officer TRAVERSA SERGIO acquire 51,407 shares of Relmada Therapeutics Inc [RLMD] - knoxdaily.com

May 01, 2025
pulisher
Apr 30, 2025

It makes sense and dollars to buy Relmada Therapeutics Inc (RLMD) stock - Sete News

Apr 30, 2025
pulisher
Apr 29, 2025

AbbVie’s Rinvoq is approved in giant cell arteritis; Relmada shares bladder cancer data - Endpoints News

Apr 29, 2025
pulisher
Apr 29, 2025

Market Insights: Relmada Therapeutics Inc (RLMD)’s Notable Drop of -44.64, Closing at 0.36 - DWinneX

Apr 29, 2025
pulisher
Apr 29, 2025

Relmada Therapeutics (RLMD) Reports Promising Phase 2 Results fo - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Da - GuruFocus

Apr 29, 2025
pulisher
Apr 28, 2025

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 - EIN News

Apr 28, 2025
pulisher
Apr 28, 2025

Taking a Closer Look At Relmada Therapeutics Inc (RLMD) Following Its Recent Trade - knoxdaily.com

Apr 28, 2025
pulisher
Apr 28, 2025

Relmada Therapeutics Reports 'Positive' Phase 2 Data for Bladder Cancer Treatment - marketscreener.com

Apr 28, 2025
pulisher
Apr 28, 2025

Relmada Therapeutics, Inc. Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 - marketscreener.com

Apr 28, 2025
pulisher
Apr 28, 2025

Relmada reports strong Phase 2 results for bladder cancer drug By Investing.com - Investing.com Canada

Apr 28, 2025
pulisher
Apr 28, 2025

Relmada reports strong Phase 2 results for bladder cancer drug - Investing.com

Apr 28, 2025
pulisher
Apr 28, 2025

SEC Form 424B5 filed by Relmada Therapeutics Inc. - Quantisnow

Apr 28, 2025
pulisher
Apr 28, 2025

Relmada Therapeutics (RLMD) Presents Positive Initial Phase 2 NDV-01 Data - StreetInsider

Apr 28, 2025
pulisher
Apr 28, 2025

Breakthrough: Relmada's New Bladder Cancer Drug Achieves 90% Disease-Free Rate in Phase 2 Trial - Stock Titan

Apr 28, 2025
pulisher
Apr 28, 2025

Relmada Therapeutics (RLMD) to Discuss NDV-01 Phase 2 Study Resu - GuruFocus

Apr 28, 2025
pulisher
Apr 28, 2025

Relmada Therapeutics Inc: Rising -85.57% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com

Apr 28, 2025
pulisher
Apr 27, 2025

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025 - GuruFocus

Apr 27, 2025
pulisher
Apr 27, 2025

Relmada Therapeutics Presents NDV-01 Data at AUA2025 Conference for High-Risk Non-Muscle Invasive Bladder Cancer - Nasdaq

Apr 27, 2025
pulisher
Apr 27, 2025

Groundbreaking Bladder Cancer Treatment Data: Relmada's NDV-01 Takes Center Stage at AUA2025 - Stock Titan

Apr 27, 2025
pulisher
Apr 25, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 25, 2025
pulisher
Apr 25, 2025

Stock Performance Spotlight: Relmada Therapeutics Inc (RLMD) Ends the Day at 0.74, Up by 6.86 - DWinneX

Apr 25, 2025
pulisher
Apr 24, 2025

Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data - The Manila Times

Apr 24, 2025
pulisher
Apr 24, 2025

Bridgeline Digital Secures Elite SOC 2 Type II Certification: What This Means for Enterprise Security - Stock Titan

Apr 24, 2025
pulisher
Apr 24, 2025

Take off with Relmada Therapeutics Inc (RLMD): Get ready for trading - Sete News

Apr 24, 2025
pulisher
Apr 23, 2025

RLMD’s price-to-free cash flow ratio: What it means for investors - uspostnews.com

Apr 23, 2025
pulisher
Apr 23, 2025

Relmada Therapeutics Inc (RLMD) receives a Neutral rating from Mizuho - knoxdaily.com

Apr 23, 2025
pulisher
Apr 22, 2025

RLMD Stock: A Comprehensive Analysis and Forecast - investchronicle.com

Apr 22, 2025
pulisher
Apr 18, 2025

Relmada Therapeutics (NASDAQ:RLMD) Trading Down 0.8% – Should You Sell? - Defense World

Apr 18, 2025

Finanzdaten der Relmada Therapeutics Inc-Aktie (RLMD)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Relmada Therapeutics Inc-Aktie (RLMD) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Shenouda Maged
Chief Financial Officer
May 19 '25
Buy
0.49
90,000
43,686
228,335
Shenouda Maged
Chief Financial Officer
May 20 '25
Buy
0.52
60,000
31,422
288,335
Shenouda Maged
Chief Financial Officer
May 16 '25
Buy
0.44
50,000
22,100
138,335
Ence Chuck
CA and CO
May 16 '25
Buy
0.45
228,961
103,330
267,931
TRAVERSA SERGIO
Chief Executive Officer
May 20 '25
Buy
0.56
147,686
82,246
734,024
TRAVERSA SERGIO
Chief Executive Officer
May 16 '25
Buy
0.45
172,314
77,472
556,338
TRAVERSA SERGIO
Chief Executive Officer
May 19 '25
Buy
0.50
30,000
14,994
586,338
TRAVERSA SERGIO
Chief Executive Officer
Sep 11 '24
Buy
2.99
51,407
153,707
384,024
TRAVERSA SERGIO
Chief Executive Officer
Sep 09 '24
Buy
2.71
55,579
150,619
299,603
TRAVERSA SERGIO
Chief Executive Officer
Sep 10 '24
Buy
2.75
33,014
90,788
332,617
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Kapitalisierung:     |  Volumen (24h):